Idioma: Ingles.
Referencias bibliográficas: 9
Paginas: 5
Archivo PDF: 70.95 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, et al. Clinical Experience with Nimotuzumab in Cuban Pediatric Patients with Brain Tumors, 2005 to 2007. MEDICC Review 2009 Summer;11(3):27–33.

2. Rivera F, Vega-Villegas M, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol. 2008;47(1):9–19.

3. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009 Sep;9(9):1199–1206.

4. Baselga J, Arteaga CL. Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. J Clin Oncol. 2005 Apr 10;23(11): 2445–59.

5. Baldwin RT, Preston-Martin S. Epidemiology of Brain Tumors in Childhood–A Review. Toxicol Appl Pharmacol. 2004 Sep 1;199(2):118–31.

6. Pollack I. Brain tumors in children. N Engl J Med. 1994 Dec 1;331(22):1500–7.

7. Broader JM. Edward M. Kennedy, Senate Stalwart, Is Dead at 77. The New York Times. 2009 Aug 26.

8. Dockerty JD, Skegg D, Williams SM. Economic effects of childhood cancer on families. J Paediatr Child. 2003 May–Jun;39(4):254–8.

9. Note that Nimotuzumab is currently approved for marketing in more than 20 countries (see www. ymbiosciences.com) and that recently the US Department of Treasury has enabled the further testing and development of Nimotuzumab for treatment of solid tumors in the United States (“YM Biosciences USA receives clearance from US Treasury Department to extend clinical program for Nimotuzumab,” The Wall Street Journal, August 10, 2009).